Effect of Vitamin D Treatment on Serum Sclerostin Level

Abstract

Objective Sclerostin is an osteocyte-secreted endogenous inhibitor of Wnt signaling. Several systemic and local factors have been suggested as possible regulators of sclerostin expression by osteocytes. In this study, we examined the effect of vitamin D treatment on sclerostin levels.

Subject and Methods 44 patients with diagnosis of vitamin D deficiency (25(OH)D≤20 ng/ml) were involved in the study. Patients had monthly intramuscular injection of 300.000 IU cholecalciferol for 3 consecutive months. Sclerostin, 25(OH)D, parathyroid hormone (PTH), calcium, phosphorus and alkaline phosphatase (ALP) levels were measured during the diagnosis and after the replacement of vitamin D.

Results 8 male and 36 female patients were enrolled in the study. Minimum age, maximum age and average age were 21, 55 and 32.02±9.26 years, respectively. A statistically significant difference was observed between the pre-treatment and post-treatment values in 25(OH)D levels (p:0.001, 10.27±4.62 ng/ml and 51.40±14.62 ng/ml, respectively), PTH levels (p:0.001, 50.32±19.05 pg/ml and 33.97±13.12 pg/ml, respectively) and sclerostin levels (p:0.002, 858.98±351.63 pg/ml and 689.52±197.92 pg/ml, respectively). No statistically significant difference, however, was found between the pre-treatment and post-treatment calcium, phosphorus and ALP levels. Correlation analysis made on pre-treatment and post-treatment sclerostin levels and 25(OH)D, PTH, calcium, phosphorus and ALP levels revealed no statistically significant correlation.

Conclusion Our findings show that the sclerostin level of patients with vitamin D deficiency decreases considerably through treatment.

Key words

sclerostin - vitamin D deficiency - parathyroid hormone

• References

• 1 Klibanski A, Adams-Campbell L, Bassford T. et al. Osteoporosis prevention, diagnosis, and therapy. JAMA 2001; 285: 785-795
• 2 Lewiecki EM. Role of sclerostin in bone and cartilage and its potential as a therapeutic target in bone diseases. Ther Adv Musculoskelet Dis 2014; 6: 48-57
• 3 Li X, Zhang Y, Kang H. et al. Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling. J Biol Chem 2005; 280: 19883-19887
• 4 Baron R, Rawadi G. Targeting the Wnt/beta-catenin pathway to regulate bone formation in the adult skeleton. Endocrinology 2007; 148: 2635-2643
• 5 Li X, Ominsky M, Niu Q. et al. Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength. J Bone Miner Res 2008; 23: 860-869
• 6 Agholme F, Li X, Isaksson H. et al. Sclerostin antibody treatment enhances metaphyseal bone healing in rats. J Bone Miner Res 2010; 25: 2412-2418
• 7 Li X, Warmington KS, Niu QT. et al. Inhibition of sclerostin by monoclonal antibody increases bone formation, bone mass and bone strength in aged male rats. J Bone Miner Res 2010; 25: 2647-2656
• 8 Holick MF, Binkley NC, Bischoff-Ferrari HA. et al. Evaluation, Treatment, and Prevention of Vitamin D Deficiency: an Endocrine Society Clinical Practice Guideline. J Clin Endocrin Metab 2011; 96: 3908
• 9 Winkler DG, Sutherland MK, Geoghegan JC. et al. Osteocyte control of bone formation via sclerostin, a novel BMP antagonist. EMBO J 2003; 22: 6267-6276
• 10 Ominsky M, Li C, Li X. et al. Inhibition of sclerostin by monoclonal antibody enhances bone healing and improves bone density and strength of nonfractured bones. J Bone Miner Res 2011; 26: 1012-1021
• 11 Pleiner-Duxneuner J, Zwettler E, Paschalis E. et al. Treatment of osteoporosis with parathyroid hormone and teriparatide. Calcif Tissue Int 2009; 84: 159-170
• 12 Gennari L, Merlotti D, Valenti R. et al. Circulating Sclerostin Levels and Bone Turnover in Type 1 and Type 2 Diabetes. J Clin Endocrinol Metab 2012; 97: 1737-1744
• 13 Gaudio A, Pennisi P, Bratengeier C. et al. Increased sclerostin serum levels associated with bone formation and resorption markers in patients with immobilization-induced bone loss. J Clin Endocrinol Metab 2010; 95: 2248-2253
• 14 Neer RM, Arnaud CD, Zanchetta JR. et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001; 344: 1434-1441
• 15 Silverberg SJ, Shane E, de la Cruz L. et al. Skeletal disease in primary hyperparathyroidism. J Bone Miner Res 1989; 4: 283-291
• 16 Yu EW, Kumbhani R, Siwila-Sackman E. et al. Acute Decline in Serum Sclerostin in Response to PTH Infusion in Healthy Men. J Clin Endocrinol Metab 2011; 96: E1848-E1851
• 17 Bellido T, Ali AA, Gubrij I. et al. Chronic elevation of parathyroid hormone in mice reduces expression of sclerostin by osteocytes: a novel mechanism for hormonal control of osteoblastogenesis. Endocrinology 2005; 146: 4577-4583
• 18 Keller H, Kneissel M. SOST is a target gene for PTH in bone. Bone 2005; 37: 148-158
• 19 Leupin O, Kramer I, Collette NM. et al. Control of the SOST bone enhancer by PTH using MEF2 transcription factors. J Bone Miner Res 2007; 22: 1957-1967
• 20 Silvestrini G, Ballanti P, Leopizzi M. et al. Effects of intermittent parathyroid hormone (PTH) administration on SOST mRNA and protein in rat bone. J Mol Histol 2007; 38: 261-269
• 21 Mirza FS, Padhi ID, Raisz LG. et al. Serum Sclerostin Levels Negatively Correlate with Parathyroid Hormone Levels and Free Estrogen Index in Postmenopausal Women. J Clin Endocrinol Metab 2010; 95: 1991-1997
• 22 Polyzos SA, Anastasilakis AD, Bratengeier C. et al. Serum sclerostin levels positively correlate with lumbar spinal bone mineral density in postmenopausal women-the six-month effect of risedronate and teriparatide. Osteoporos Int 2012; 23: 1171-1176
• 23 Ardawi MS, Al-Kadi HA, Rouzi AA. et al. Determinants of serum sclerostin in healthy pre- and postmenopausal women. J Bone Miner Res 2011; 26: 2812-2822
• 24 van Lierop AH, Witteveen JE, Hamdy NA. et al. Patients with primary hyperparathyroidism have lower circulating sclerostin levels than euparathyroid controls. Eur J Endocrinol 2010; 163: 833-837
• 25 Kaji H, Imanishi Y, Sugimoto T. et al. Comparisons of serum sclerostin levels among patients with postmenopausal osteoporosis, primary hyperparathyroidism and osteomalacia. Exp Clin Endocrinol Diabetes 2011; 119: 440-444
• 26 Costa AG, Cremers S, Rubin MR. et al. Circulating sclerostin in disorders of parathyroid gland function. J Clin Endocrinol Metab 2011; 96: 3804-3810
• 27 Claes KJ, Viaene L, Heye S. et al. Sclerostin: Another Vascular Calcification Inhibitor?. J Clin Endocrinol Metab 2013; 98: 3221-3228